Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2015-04-29, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: SVA/20150429/20-F/1/000.htm SEC Original: a14-26055_120f.htm
None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 55,809,661 common shares as of December 31, 2014 o Yes x No o Yes x No x Yes o No x Yes o No Large accelerated filer

---

---

Webplus: SVA/20150429/20-F/2_EX-8.1/000.htm SEC Original: a14-26055_1ex8d1.htm
List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company

---

---

Webplus: SVA/20150429/20-F/3_EX-12.1/000.htm SEC Original: a14-26055_1ex12d1.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

---

---

Webplus: SVA/20150429/20-F/4_EX-12.2/000.htm SEC Original: a14-26055_1ex12d2.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

---

---

Webplus: SVA/20150429/20-F/5_EX-13.1/000.htm SEC Original: a14-26055_1ex13d1.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Weidong Yin Weidong Yin Chief Executive Officer EX-13.1 5 a14-26055_1ex13d1.htm EX-13.1

---

---

Webplus: SVA/20150429/20-F/6_EX-13.2/000.htm SEC Original: a14-26055_1ex13d2.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Nan Wang Chief Financial Officer EX-13.2 6 a14-26055_1ex13d2.htm EX-13.2

---

---

Webplus: SVA/20150429/20-F/7_EX-15.1/000.htm SEC Original: a14-26055_1ex15d1.htm
Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan of our reports dated April 29, 2015, with respect to

---

---

Webplus: SVA/20150429/20-F/8_EX-15.2/000.htm SEC Original: a14-26055_1ex15d2.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining the Company’s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to the Company’s 2012 Share Incentive Plan of our report dated April 29, 2013 with respect to the consolidated financial

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2015-04-29, XBRL Interactive FinancialsCIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085